Research programme: vaccines - SK Chemicals

Drug Profile

Research programme: vaccines - SK Chemicals

Alternative Names: NBP-607; NBP-613; NBP-614; NBP-615

Latest Information Update: 24 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SK Chemicals
  • Class Influenza virus vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 24 Apr 2017 SK Chemicals is conducting preclinical development for vaccines in South Korea (SK Chemicals website, April 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in South Korea (Parenteral)
  • 01 Nov 2011 Preclinical trials in Influenza virus infections in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top